NCT07414472 (PES) is a clinical trial in Post Extubation Stridor, sponsored by University Hospital, Antwerp.

Who is sponsoring NCT07414472?

NCT07414472 is sponsored by University Hospital, Antwerp.

What condition does NCT07414472 study?

NCT07414472 studies Post Extubation Stridor.

Is NCT07414472 still recruiting?

NCT07414472 is currently recruiting now. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT07414472: PES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Is High Resolution Endotracheal Tube Leak Data Indicative of the Development of Post-extubation Stridor in Children?

Recruiting now Last updated 17 February 2026

What this trial tests

trial in Post Extubation Stridor in 400 participants. Currently enrolling.

Timeline

30 June 2025

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	University Hospital, Antwerp
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	30 June 2025
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across Belgium

Conditions studied

Post Extubation Stridor — all drugs for Post Extubation Stridor →

Sponsor

University Hospital, Antwerp

Who can join

Under 16, any sex, with Post Extubation Stridor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Post extubation stridor (PES) is a common and possibly serious complication of invasive ventilation via endotracheal tube (ETT) in pediatric intensive care (PICU) patients. The source of the PES is either temporary in the case of post-intubation laryngeal edema, or long-term in the case of subglottic stenosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Antwerp trials

Trials by the same sponsor.

NCT07455422 — A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurr · NA · not yet recruiting
NCT07020715 — A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis · Phase 2 · not yet recruiting
NCT07443761 — Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital. · active not recruiting
NCT06372847 — DISE-HNS Effect Study · NA · recruiting
NCT07189091 — CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07414472 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Antwerp
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07414472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing